evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

11 questions · 11 findings · 7 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 18.2%Low 3 · 27.3%Moderate 4 · 36.4%High 2 · 18.2%

Intervention not reported

28‐day all‐cause mortality · hospitalised adults with COVID‐19 (moderate to severe disease)

The intervention probably leads to lower 28‐day all‐cause mortality (moderate certainty).

1 finding from 1 review

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

All‐cause mortality (by day 28) · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Intervention not reported

All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…

It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).

1 finding from 1 review

Azithromycin vs placebo or usual care

All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…

Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs human immunoglobulin

All‐cause mortality at up to day 28 · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 compared with human immunoglobulin (low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs standard plasma

All‐cause mortality at up to day 28 · individuals with moderate to severe disease

It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with standard plasma (very low certainty).

1 finding from 1 review

Remdesivir and standard care vs placebo or usual care

All‐cause mortality at up to day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Remdesivir and standard care vs placebo or usual care

All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

All‐cause mortality at up to day 28 ‐ total · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 ‐ total compared with placebo or standard care alone (high certainty).

1 finding from 1 review